Vertex drops mRNA cystic fibrosis program over 'tolerability' issues

May 4, 2026 07:29 PM EDT R&D Ver­tex drops mR­NA cys­tic fi­bro­sis pro­gram over 'tol­er­a­bil­i­ty' is­sues Lei Lei Wu News Reporter Ver­tex Phar­ma­ceu­ti­cals said it has dropped de­vel­op­ment of an mR­NA-based cys­tic fi­bro­sis ther­a­py, af­ter fac­ing chal­lenges de­liv­er­ing the ge­net­ic med­i­cine sim­i­lar to those that have … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER